Skip to main content

Niagen Bioscience Inc (NAGE) Stock Forecast

Data as of May 9, 2026

Healthcare · Current price $4.20 (+0.12%)

Consensus Target
$14.00
Upside
+138.1%
Analysts
3
Rating
Buy(2.00)

Price Target Range

Low $14.00High $14.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy3
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

NAGE vs Sector & Market

MetricNAGEHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count3819
Target Upside+138.1%+1710.8%+16.4%
P/E Ratio20.563.2827.60

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$146M$148M$150M4
2027-03-31$36M$37M$38M1
2027-06-30$40M$41M$42M2
2027-09-30$45M$47M$48M2
2027-12-31$46M$47M$49M1
2028-03-31$43M$45M$46M1
2028-06-30$49M$50M$52M1
2028-09-30$55M$57M$59M1
2028-12-31$56M$58M$60M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$0.16$0.27$0.373
2027-03-31$0.04$0.05$0.051
2027-06-30$0.07$0.08$0.081
2027-09-30$0.10$0.11$0.111
2027-12-31$0.10$0.10$0.111
2028-03-31$0.08$0.08$0.081
2028-06-30$0.11$0.12$0.131
2028-09-30$0.15$0.16$0.171
2028-12-31$0.14$0.15$0.161

Frequently Asked Questions

What is the analyst consensus for NAGE?

The consensus among 3 analysts covering Niagen Bioscience Inc (NAGE) is Buy with an average price target of $14.00.

What is the highest price target for NAGE?

The highest analyst price target for NAGE is $14.00.

What is the lowest price target for NAGE?

The lowest analyst price target for NAGE is $14.00.

How many analysts cover NAGE?

3 analysts have issued ratings for Niagen Bioscience Inc in the past 12 months.

Is NAGE a buy or sell right now?

Based on 3 analyst ratings, NAGE has a consensus rating of Buy (2.00/5) with a +138.1% upside to the consensus target of $14.00.

What are the earnings estimates for NAGE?

Analysts estimate NAGE will report EPS of $0.27 for the period ending 2026-12-31, with revenue estimated at $148M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.